ERBB2 and breast cancer: Another study proved a positive correlation between HER2 status and FoxM1 expression in breast cancer tissue compared to normal breast counterpart [73–75], suggesting that FoxM1 is a downstream target of HER2 and could be used as a marker of HER2 overexpression.